Efficacy of Combination Therapy with the JAK Inhibitor Baricitinib in the Treatment of COVID-19
© The Author(s) 2022..
Coronavirus disease-19 (COVID-19), resulting from infection with SARS-CoV-2, spans a wide spectrum of illness. In severely ill patients, highly elevated serum levels of certain cytokines and considerable cytolytic T cell infiltrates in the lungs have been observed. These same patients may bear low to negligible viral burdens suggesting that an overactive immune response, often termed cytokine storm, contributes to the severity of COVID-19. We report the safety and efficacy of baricitinib combined with remdesivir and dexamethasone in a retrospective review of 45 hospitalized patients with COVID-19 pneumonia at a tertiary academic medical center. Patients received 7-day course of baricitinib, 5-day course of remdesivir, and 10-day course of dexamethasone. Clinical status and biomarkers were obtained daily. Outcomes assessed include mortality, duration of hospitalization, presence of shock, need for supplemental oxygen, need for non-invasive ventilation, need for mechanical ventilation, and development of thrombosis. Obesity and multiple medical comorbidities were associated with hospitalization in the setting of COVID-19. Treated patients demonstrated rapid declines of C-reactive protein (CRP), ferritin and D-dimer with gradual improvement in hemoglobin, platelet counts, and clinical status. Only 2 of 45 (4.4%) treated patients required mechanical ventilation after initiating treatment, and there were six deaths (13.3%). Only 2 of 45 (4.4%) treated patients required mechanical ventilation after initiating treatment. There were six deaths (13.3%) and these were associated with lower BMI. These findings support the utility of immunosuppression via JAK inhibition in moderate to severe COVID-19 pneumonia.
SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s42399-022-01121-4.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
SN comprehensive clinical medicine - 4(2022), 1 vom: 01., Seite 42 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Thoms, Brendan L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Baricitinib |
|---|
| Anmerkungen: |
Date Revised 29.12.2022 published: Print-Electronic UpdateOf: Res Sq. 2021 Sep 08;:. - PMID 34518834 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1007/s42399-022-01121-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336141181 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336141181 | ||
| 003 | DE-627 | ||
| 005 | 20231225231449.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s42399-022-01121-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1120.xml |
| 035 | |a (DE-627)NLM336141181 | ||
| 035 | |a (NLM)35079694 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Thoms, Brendan L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy of Combination Therapy with the JAK Inhibitor Baricitinib in the Treatment of COVID-19 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 29.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a UpdateOf: Res Sq. 2021 Sep 08;:. - PMID 34518834 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2022. | ||
| 520 | |a Coronavirus disease-19 (COVID-19), resulting from infection with SARS-CoV-2, spans a wide spectrum of illness. In severely ill patients, highly elevated serum levels of certain cytokines and considerable cytolytic T cell infiltrates in the lungs have been observed. These same patients may bear low to negligible viral burdens suggesting that an overactive immune response, often termed cytokine storm, contributes to the severity of COVID-19. We report the safety and efficacy of baricitinib combined with remdesivir and dexamethasone in a retrospective review of 45 hospitalized patients with COVID-19 pneumonia at a tertiary academic medical center. Patients received 7-day course of baricitinib, 5-day course of remdesivir, and 10-day course of dexamethasone. Clinical status and biomarkers were obtained daily. Outcomes assessed include mortality, duration of hospitalization, presence of shock, need for supplemental oxygen, need for non-invasive ventilation, need for mechanical ventilation, and development of thrombosis. Obesity and multiple medical comorbidities were associated with hospitalization in the setting of COVID-19. Treated patients demonstrated rapid declines of C-reactive protein (CRP), ferritin and D-dimer with gradual improvement in hemoglobin, platelet counts, and clinical status. Only 2 of 45 (4.4%) treated patients required mechanical ventilation after initiating treatment, and there were six deaths (13.3%). Only 2 of 45 (4.4%) treated patients required mechanical ventilation after initiating treatment. There were six deaths (13.3%) and these were associated with lower BMI. These findings support the utility of immunosuppression via JAK inhibition in moderate to severe COVID-19 pneumonia | ||
| 520 | |a SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s42399-022-01121-4 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Baricitinib | |
| 650 | 4 | |a Coronavirus disease-19 (COVID-19) | |
| 650 | 4 | |a Critical care | |
| 650 | 4 | |a Cytokine storm | |
| 650 | 4 | |a JAK inhibitor | |
| 700 | 1 | |a Gosselin, Jeanne |e verfasserin |4 aut | |
| 700 | 1 | |a Libman, Bonita |e verfasserin |4 aut | |
| 700 | 1 | |a Littenberg, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Budd, Ralph C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t SN comprehensive clinical medicine |d 2019 |g 4(2022), 1 vom: 01., Seite 42 |w (DE-627)NLM300071965 |x 2523-8973 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2022 |g number:1 |g day:01 |g pages:42 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s42399-022-01121-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2022 |e 1 |b 01 |h 42 | ||